The HIF-2 transcription factor mediates resistance to ferroptosis in pancreatic cancer
Molecular Cell · 2026
DOI: 10.1016/j.molcel.2026.03.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Cell, 2026. Verfasst von Maimon E Hubbi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Ludwig Institute for Cancer Research, New York, NY, USA. Ele…. Hauptthemen laut MEDLINE: Ferroptosis, Pancreatic Neoplasms, Basic Helix-Loop-Helix Proteins, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Pancreatic Cancer Research Fund, National Institutes of Health.
Abstract (Originalsprache)
Ferroptosis is an iron-dependent form of cell death converging on lipid peroxidation first identified by examining compounds with enhanced lethality to KRAS mutant cells. Despite over 90% of pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations, PDAC exhibits relative resistance to ferroptosis compared with other tumor types, and the mechanisms behind this resistance remain unclear. Here, we report that exposure to pancreatic tumor interstitial fluid in synergy with hypoxia induced robust protection against ferroptosis in a manner dependent on the hypoxia-inducible transcription factor 2 (HIF-2). HIF-2 upregulates the expression of both components of the system Xc- cystine transporter and transsulfuration pathway enzymes CBS and CTH to increase intracellular cysteine levels, enabling anti-ferroptotic glutathione production. HIF-2 also induces the Parkin mitophagy factor and suppresses mitochondrial function and reactive oxygen species (ROS) generation. Altogether, our findings uncover an unforeseen role of the HIF-2 transcription factor as a coordinator of anti-ferroptotic mechanisms in pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Ludwig Institute for Cancer Research, New York, NY, USA. Electronic address: mhubbi1@jhmi.edu.
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Ludwig Institute for Cancer Research, New York, NY, USA; Medical Scientist Training Program, Johns Hopkins School of Medicine, Bal…
- Department of Biomedical Engineering, University of Connecticut Health, Farmington, CT, USA.
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Medicine and Abramson Cancer Center and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Medicine and Abramson Cancer Center and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Medical Scientist Training Program, Univer…
Förderung
- NCI NIH HHS
- Pancreatic Cancer Research Fund
- National Institutes of Health
- Ludwig Institute for Cancer Research
Zitieren
APA
Hubbi, M. E., Wang, C. L., Suhail, Y., Almasri, N. L., Xie, J., Hollander, E. E., Kshitiz, Muir, A., Stanger, B. Z., & Dang, C. V. (2026). The HIF-2 transcription factor mediates resistance to ferroptosis in pancreatic cancer. Molecular Cell. https://doi.org/10.1016/j.molcel.2026.03.007
Vancouver
Hubbi ME, Wang CL, Suhail Y, Almasri NL, Xie J, Hollander EE, et al. The HIF-2 transcription factor mediates resistance to ferroptosis in pancreatic cancer. Molecular Cell. 2026. doi:10.1016/j.molcel.2026.03.007
BibTeX
@article{Hubbi2026,
author = {Hubbi, Maimon E and Wang, Catherine L and Suhail, Yasir and Almasri, Nadia L and Xie, Jane and Hollander, Erin E and Kshitiz and Muir, Alexander and Stanger, Ben Z and Dang, Chi V},
title = {The HIF-2 transcription factor mediates resistance to ferroptosis in pancreatic cancer},
journal = {Molecular Cell},
year = {2026},
doi = {10.1016/j.molcel.2026.03.007}
}
EUVIMED